Incretin-based therapies were associated with a decrease in serum alanine aminotransferase (ALT) (−14.1 IU/L [8.3–19.8], p < 0.0001), as indicated by a meta-analysis of four studies (136 participants with NAFLD), with two of them indicating a reduction in liver fibrosis [162]. Here, GPT is linked to metabolic dysfunction-associated steatotic liver disease.